Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences and Roche Holdings AG.
The global enzymes market is expected to decline from $7.98 billion in 2019 to $7.81 billion in 2020 at a compound annual growth rate (CAGR) of -2.20%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $11.92 billion in 2023 at a CAGR of 15.15%.
The enzymes market consists of sales of enzymes to treat diseases. An enzyme is a protein or RNA formed by living cells that are extremely specific to its substrates and highly catalytic. Enzymes constitute a very significant class of biological macromolecular catalysts. Enzymes that are used in medical applications in their isolated or conjugated form with other drugs or therapies are known as therapeutic enzymes. Therapeutic enzymes are used in the treatment of various diseases including cancer, inflammatory disorders, cardiovascular diseases, and pain management.
North America was the largest region in the enzymes market in 2019.
In May 2020, AbbVie Inc., a US-based biopharmaceutical company, acquired Allergan plc for $63 billion. This acquisition significantly expands and diversifies AbbVie’s revenue base and complements existing leadership positions in Immunology, with Humira and recently launched Skyrizi and Rinvoq, and Hematologic Oncology, with Imbruvica and Venclexta. Allergan plc is an Ireland-based pharmaceutical company engaged in the research, development, and manufacture of pharmaceutical and enzymes-based therapeutic products.
The enzymes market covered in this report is segmented by product type into asparaginase; lipase; protease; nattokinase; chitinase; serratiopeptidase; collagenase; ligase; others and by application into leukemia; stomach disorders; antitumor; skin ulcers; gaucher disease; fabry disease; others.
The development of new approaches to treat cancer using enzymes is a key trend gaining popularity in the enzymes market. Major universities and companies are investing in researches focusing on evolving new solutions in enzyme therapies for cancer treatment. For example, in August 2018, Kyn Therapeutics, a US-based company that focuses on improving outcomes for cancer patients, along with the Cancer Prevention and Research Institute of Texas and the American Cancer Society funded the research introducing a new approach to cancer care using enzyme therapy to boost the immune system and fight back. The enzyme, PEG-KYNase, does not destroy cancer cells specifically but rather enables the immune system itself to remove unwanted cells. PEG-KYNase is designed to degrade the metabolite produced by numerous tumors known as kynurenine, which suppresses the immune system.
The growing prevalence of cancer and the need for drug-metabolizing enzymes (DMEs) for chemotherapy are expected to drive the growth of the enzymes market in the coming years. The activation of enzymes in a human body help destroy the cancer cells and breaks down the tumor. The expression and function of DMEs in cancer patients’ tumor tissues and metabolic organs is therefore essential and help patients for whom reaction to anticancer drugs and response to chemotherapy is low. According to the World Health Organization (WHO), 9.6 million deaths occurred in 2018 due to cancer and about 70% of deaths from cancer occur in low- and middle-income countries. Therefore, the increasing prevalence of cancer, which can be cured using therapeutic enzymes, is predicted to drive the growth of the enzymes market.
Our reports have been used by over 10K customers, including:
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 220.127.116.11) - Drugs in Development, 2021 Summary Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 18.104.22.168) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed...
131 pages •
By Global Industry Analysts
• Apr 2021
- Global Lysosomal Storage Diseases Market to Reach $10.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Lysosomal Storage Diseases estimated at US$7 Billion in the year 2020, is projected to reach a revised size of US$10.3 Billion by 2027, growing at a CAGR of 5.6% over the analysis period...
Readers of one of the analyst’s media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021.The analyst has conducted similar studies among the same targeted respondents since 2012.
Where applicable, the study presents year-over-year...
Nocturia (Genitourinary Disorders) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Nocturia - Drugs in Development, 2021, provides an overview of the Nocturia (Genito Urinary System And Sex Hormones) pipeline landscape. Nocturia is defined...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
703 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Mar 2021
Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source. According to the analysis,...
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 22.214.171.124) - Drugs in Development, 2021 Summary Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 126.96.36.199) pipeline Target constitutes close to 26 molecules. Out of which approximately 24 molecules are developed by companies and remaining...
The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period. The protein A resin market has witnessed increasing consumption due to increased monoclonal antibody production on account of the pandemic situation worldwide.. Growth in the market can primarily...
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 188.8.131.52) - Drugs in Development, 2021 Summary Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 184.108.40.206) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes...
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 220.127.116.11) - Drugs in Development, 2021 Summary According to the recently published report ’SerineThreonine Protein Kinase Pim 2 - Drugs in Development, 2021’; Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.